| sess_SDA-2026-04-08- | How do host cell factors influence the conformation and propagation properties o | 0.95 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| sess_SDA-2026-04-08- | While the study shows 53BP1 forms phase-separated foci driven by dilncRNAs, it's | 0.95 | 7 | 7 | completed | 2026-04-10 | SDA-2026-04-08-gap-pubmed-20260406-062229-3ab00c95 |
| sess_gut-brain-ad | Gut-Brain Axis Therapeutics for Alzheimer's Disease? | 0.94 | 7 | 4 | completed | 2026-04-10 | gut-brain-ad |
| sess_sda-2026-04-01- | Why do entorhinal cortex layer II stellate neurons die first in AD? Their unique | 0.95 | 7 | 6 | completed | 2026-04-10 | sda-2026-04-01-gap-004 |
| sess_sda-2026-04-01- | PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns | 0.91 | 7 | 7 | completed | 2026-04-10 | sda-2026-04-01-gap-005 |
| sess_SDA-2026-04-10- | How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa | 0.94 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-08-gap-pubmed-20260406-062212-b66510d9 |
| sess_SDA-2026-04-10- | Can circadian interventions reverse microglial priming independent of sleep disr | 0.95 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| sess_SDA-2026-04-10- | Do different priming stimuli require distinct therapeutic approaches or share co | 0.93 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-08-gap-debate-20260406-062039-f02efa4b |
| sess_SDA-2026-04-10- | What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie | 0.86 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| sess_SDA-2026-04-10- | Do tau-containing vesicles exhibit unique surface glycosylation patterns that di | 0.95 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| sess_SDA-2026-04-10- | Which specific post-translational modifications on pathological tau create drugg | 0.50 | 0 | 4 | completed | 2026-04-10 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| sess_SDA-2026-04-10- | Can nanobodies achieve selective membrane penetration into tau-containing vesicl | 0.95 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| sess_SDA-2026-04-10- | TREM2 Therapeutic Strategy Post-INVOKE-2? | 0.95 | 7 | 4 | completed | 2026-04-10 | trem2-ad |
| sess_SDA-2026-04-10- | Astrocyte reactivity subtypes in neurodegeneration | 0.95 | 7 | 4 | completed | 2026-04-10 | sda-2026-04-01-gap-007 |
| sess_SDA-2026-04-10- | GBA-Synuclein Loop: Therapeutic Strategies for Parkinson's Disease? | 0.89 | 7 | 4 | completed | 2026-04-10 | gba-pd |
| sess_SDA-2026-04-08- | The debate noted clinical failures of TNF-α and IL-6 inhibitors in AD despite th | 0.79 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| sess_SDA-2026-04-08- | The debate identified fundamental druggability challenges for these targets due | 0.95 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| sess_SDA-2026-04-08- | The highest-ranked hypothesis assumes senescence reversibility through metabolic | 0.95 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-debate-20260406-062101-7751c220 |
| sess_SDA-2026-04-08- | The authors identify SPI1 as a potential transcription factor regulating the hub | 0.93 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| sess_SDA-2026-04-08- | The study reports that complement-mediated synaptic elimination produces both co | 0.83 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062128-34a47c4e |
| sess_SDA-2026-04-08- | While the abstract establishes that intercellular transmission occurs for variou | 0.95 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062207-5a703c17 |
| sess_SDA-2026-04-08- | The study identifies ADCY8 as associated with migratory distance differences and | 0.95 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| sess_SDA-2026-04-08- | While APOE4 disrupts microglial metabolism broadly, the debate didn't identify w | 0.92 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| sess_SDA-2026-04-08- | The abstract notes that clinical presentations overlap across different myelopat | 0.86 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| sess_SDA-2026-04-08- | The paper describes memory-based migration routes maintained across generations | 0.95 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| sess_astrocyte-subty | Astrocyte Reactivity Subtypes in Neurodegeneration | 0.95 | 7 | 4 | completed | 2026-04-09 | astrocyte-subtypes |
| sess_sda-2026-04-01- | Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi | 0.91 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-008 |
| sess_sda-2026-04-01- | Microglia activate astrocytes via IL-1alpha/TNF/C1q, and reactive astrocytes fee | 0.90 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-009 |
| sess_sda-2026-04-01- | APOE4 differs from APOE3 by C112R causing domain interaction that alters lipid b | 0.89 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-010 |
| sess_sda-2026-04-01- | Multiple NDDs converge on autophagy-lysosome dysfunction. Are there universal th | 0.90 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-011 |
| sess_sda-2026-04-01- | Can speech, gait, retinal imaging, sleep, and smartphone data detect neurodegene | 0.95 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-012 |
| sess_sda-2026-04-01- | Senolytics targeting p16/p21+ senescent astrocytes and microglia may reduce SASP | 0.89 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-013 |
| sess_sda-2026-04-01- | SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation re | 0.83 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-014 |
| sess_sda-2026-04-01- | Analysis question not specified | 0.81 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-20260401231108 |
| sess_sda-2026-04-01- | Analysis question not specified | 0.53 | 1 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-9137255b |
| sess_sda-2026-04-01- | Can gut-brain axis modulation prevent or slow Alzheimer's disease pathology? | 0.95 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-003 |
| sess_sda-2026-04-01- | How to break the GBA-alpha-synuclein bidirectional loop for Parkinson's Disease | 0.90 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-002 |
| sess_sda-2026-04-01- | What are the most promising therapeutic strategies for targeting TREM2 in Alzhei | 0.95 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-001 |
| sess_sda-2026-04-01- | Analysis question not specified | 0.87 | 3 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| sess_sda-2026-04-01- | Sleep disruption as cause and consequence of neurodegeneration | 0.91 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-v2-18cf98ca |
| sess_sda-2026-04-01- | RNA binding protein dysregulation across ALS FTD and AD | 0.88 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-v2-68d9c9c1 |
| sess_sda-2026-04-01- | Synaptic pruning by microglia in early AD | 0.95 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-v2-691b42f1 |
| sess_sda-2026-04-01- | Mitochondrial transfer between astrocytes and neurons | 0.95 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-v2-89432b95 |
| sess_sda-2026-04-01- | Epigenetic clocks and biological aging in neurodegeneration | 0.93 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-v2-bc5f270e |
| sess_sda-2026-04-01- | Perivascular spaces and glymphatic clearance failure in AD | 0.95 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-v2-ee5a5023 |
| sess_sda-2026-04-01- | What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's | 0.95 | 7 | 4 | completed | 2026-04-06 | sda-2026-04-01-gap-20260401-225149 |
| sess_SDA-2026-04-06- | TREM2 Therapeutic Strategy Post-INVOKE-2 | 0.93 | 7 | 4 | completed | 2026-04-06 | SDA-2026-04-06-gap-001 |
| sess_SDA-2026-04-04- | Neuroinflammation and microglial priming in early AD | 0.95 | 7 | 3 | completed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| sess_SDA-2026-04-04- | Neuroinflammation and microglial priming in early Alzheimer's Disease | 0.95 | 7 | 3 | completed | 2026-04-04 | SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404 |
| sess_SDA-2026-04-04- | Tau propagation mechanisms and therapeutic interception points | 0.95 | 7 | 3 | completed | 2026-04-04 | SDA-2026-04-04-gap-tau-prop-20260402003221 |